Wang Xinchun, Li Qi, Kang Jianbang, Zhang Zheng, Song Yan, Yin Donghong, Guo Qian, Song Junli, Li Xiaoxia, Wang Shuyun, Duan Jinju
Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Department of Pharmacy, School of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Infect Drug Resist. 2021 Feb 5;14:449-457. doi: 10.2147/IDR.S292820. eCollection 2021.
To identify novel sequence types 4564 (ST4564) carbapenem-resistant (CRKP). Characterizing the feature of the clinic, resistance, and virulence of a co-producing NDM-1 and CTX-M-9 family and mcr-1 ST4564 strain.
A novel ST4564 CRKP was collected from June 2018 to July 2018. We investigated its antimicrobial susceptibility by the microdilution method. Using the modified carbapenem inactivation method (mCIM) to screen phenotype of carbapenemases. Resistance mechanisms, virulence-associated genes, multilocus sequence typing (MLST), and capsular serotypes were characterized by polymerase chain reaction (PCR) and DNA sequencing. Next-generation sequencing (NGS) was carried out to determine the genetic features of carbapenem resistance and virulence.
ST4564, co-carrying NDM-1, CTX-M-9 and mcr-1, was resistant to carbapenems, cephamycin, third- or fourth-generation cephalosporins, β-lactam combination agents, quinolones and tigecycline but remained susceptible to amikacin (AMK) and colistin (COL). Through the NGS analysis with the G+C content of 56.65%, multiple resistance and virulence genomes were detected. The genes encoding the β-lactams, aminoglycosides, quinolones, macrolides, sulfonamide, polysaccharide capsule, type-I fimbriae cluster, siderophore genes, transporter and pumps, T6SS and pullulanase secretion protein. goeBURST analysis showed that ST4564 belonged to the CC1571 and it was not related to the prevalent high-risk clones.
We first identified the novel ST4564 CRKP. Our finding suggested that the urgent need for infection control of the new clone to prevent it from becoming a high-risk clone of CRKP.
鉴定新型序列类型4564(ST4564)耐碳青霉烯类肺炎克雷伯菌(CRKP)。对一株同时产NDM-1和CTX-M-9家族以及mcr-1的ST4564菌株的临床特征、耐药性和毒力进行表征。
2018年6月至2018年7月收集到一株新型ST4564 CRKP。采用微量稀释法研究其抗菌药敏性。使用改良碳青霉烯灭活方法(mCIM)筛选碳青霉烯酶表型。通过聚合酶链反应(PCR)和DNA测序对耐药机制、毒力相关基因、多位点序列分型(MLST)和荚膜血清型进行表征。进行二代测序(NGS)以确定碳青霉烯耐药性和毒力的遗传特征。
ST4564同时携带NDM-1、CTX-M-9和mcr-1,对碳青霉烯类、头孢霉素、第三代或第四代头孢菌素、β-内酰胺类联合制剂、喹诺酮类和替加环素耐药,但对阿米卡星(AMK)和黏菌素(COL)仍敏感。通过NGS分析,G+C含量为56.65%,检测到多个耐药和毒力基因组。编码β-内酰胺类、氨基糖苷类、喹诺酮类、大环内酯类、磺胺类、多糖荚膜、I型菌毛簇、铁载体基因、转运蛋白和泵、T6SS以及支链淀粉酶分泌蛋白的基因。goeBURST分析表明ST4564属于CC1571,且与流行的高风险克隆无关。
我们首次鉴定出新型ST4564 CRKP。我们的发现表明迫切需要对该新克隆进行感染控制以防止其成为CRKP的高风险克隆。